The latest price target for Alaunos Therapeutics (NASDAQ:TCRT) was reported by HC Wainwright & Co. on August 16, 2023. The analyst firm set a price target for $0.00 expecting TCRT to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Alaunos Therapeutics (NASDAQ:TCRT) was provided by HC Wainwright & Co., and Alaunos Therapeutics downgraded their neutral rating.

The last upgrade for Alaunos Therapeutics Inc happened on May 15, 2023 when HC Wainwright & Co. raised their price target to $1.5. HC Wainwright & Co. previously had a neutral for Alaunos Therapeutics Inc.

The last downgrade for Alaunos Therapeutics Inc happened on August 16, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Alaunos Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alaunos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alaunos Therapeutics was filed on August 16, 2023 so you should expect the next rating to be made available sometime around August 16, 2024.

While ratings are subjective and will change, the latest Alaunos Therapeutics (TCRT) rating was a downgraded with a price target of $0.00 to $0.00. The current price Alaunos Therapeutics (TCRT) is trading at is $2.25, which is out of the analyst’s predicted range.